David A. Fruman - Publications

University of California, Irvine, Irvine, CA 
Oncology, Cell Biology

58 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. Cell. 170: 605-635. PMID 28802037 DOI: 10.1016/j.cell.2017.07.029  0.6
2017 Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. The Journal of Clinical Investigation. 127: 2438. PMID 28569734 DOI: 10.1172/JCI95182  0.6
2017 Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR. Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling. The Journal of Biological Chemistry. 292: 5608. PMID 28363934 DOI: 10.1074/jbc.A117.305602  0.6
2016 Hong CA, Cho SK, Edson JA, Kim J, Ingato D, Pham B, Chuang A, Fruman D, Kwon YJ. Viral/Nonviral Chimeric Nanoparticles to Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing. Acs Nano. PMID 27472284 DOI: 10.1021/acsnano.6b04155  0.96
2015 Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. PMID 26460954 DOI: 10.18632/oncotarget.6051  0.96
2015 Beagle BR, Nguyen DM, Mallya S, Tang SS, Lu M, Zeng Z, Konopleva M, Vo TT, Fruman DA. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget. 6: 2088-100. PMID 25576920  0.96
2014 Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman DA. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. Plos One. 9: e99486. PMID 24915189 DOI: 10.1371/journal.pone.0099486  0.96
2014 Zhang Z, Eckert MA, Ali MM, Liu L, Kang DK, Chang E, Pone EJ, Sender LS, Fruman DA, Zhao W. DNA-scaffolded multivalent ligands to modulate cell function. Chembiochem : a European Journal of Chemical Biology. 15: 1268-73. PMID 24803415 DOI: 10.1002/cbic.201402100  0.96
2014 Fruman DA, Cantley LC. Idelalisib--a PI3Kδ inhibitor for B-cell cancers. The New England Journal of Medicine. 370: 1061-2. PMID 24620870 DOI: 10.1056/NEJMe1400055  0.96
2014 Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman DA. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. Plos One. 9: e88865. PMID 24586420 DOI: 10.1371/journal.pone.0088865  0.6
2013 Zhang Z, Ali MM, Eckert MA, Kang DK, Chen YY, Sender LS, Fruman DA, Zhao W. A polyvalent aptamer system for targeted drug delivery. Biomaterials. 34: 9728-35. PMID 24044994 DOI: 10.1016/j.biomaterials.2013.08.079  0.96
2013 Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CTH, Ong ST. Targeting of the MNK-eIF4E axis in blast crisis Chronic myeloid leukemia inhibits leukemia stem cell function Proceedings of the National Academy of Sciences of the United States of America. 110: E2298-E2307. PMID 23737503 DOI: 10.1073/pnas.1301838110  0.6
2013 Yea SS, Fruman DA. Achieving cancer cell death with PI3K/mTOR-targeted therapies. Annals of the New York Academy of Sciences. 1280: 15-8. PMID 23551096 DOI: 10.1111/nyas.12028  0.96
2013 So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, ... Fruman DA, et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. The Journal of Biological Chemistry. 288: 5718-31. PMID 23275335 DOI: 10.1074/jbc.M112.379446  0.96
2013 Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 27: 586-94. PMID 23090679 DOI: 10.1038/leu.2012.276  0.96
2012 Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 120: 2679-89. PMID 22826565 DOI: 10.1182/blood-2011-11-393934  0.96
2012 Janes MR, Fruman DA. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia. Methods in Molecular Biology (Clifton, N.J.). 821: 251-65. PMID 22125070 DOI: 10.1007/978-1-61779-430-8_15  0.6
2011 Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. The Biochemical Journal. 439: 299-311. PMID 21767261 DOI: 10.1042/BJ20110853  0.96
2011 Yea SS, Fruman DA. Cell signaling. New mTOR targets Grb attention. Science (New York, N.Y.). 332: 1270-1. PMID 21659593 DOI: 10.1126/science.1208071  0.96
2011 Casey SC, Nelson EL, Turco GM, Janes MR, Fruman DA, Blumberg B. B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR. Molecular Endocrinology (Baltimore, Md.). 25: 933-43. PMID 21436254 DOI: 10.1210/me.2010-0486  0.96
2010 Janes MR, Fruman DA. Targeting TOR dependence in cancer. Oncotarget. 1: 69-76. PMID 20657741 DOI: 10.18632/oncotarget.110  0.6
2010 Chen J, Limon JJ, Blanc C, Peng SL, Fruman DA. Foxo1 regulates marginal zone B-cell development. European Journal of Immunology. 40: 1890-6. PMID 20449867 DOI: 10.1002/eji.200939817  0.72
2010 Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, ... Fruman DA, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine. 16: 205-13. PMID 20072130 DOI: 10.1038/nm.2091  0.96
2009 Oak JS, Chen J, Peralta RQ, Deane JA, Fruman DA. The p85beta regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. Autoimmunity. 42: 447-58. PMID 19811262 DOI: 10.1080/08916930902911746  0.96
2009 Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova TV, Liaw L, Prudovsky I, Thorpe PE, Miura N, Cantley LC, Alitalo K, Fruman DA, Vary CP. Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 238: 2670-9. PMID 19705443 DOI: 10.1002/dvdy.22078  0.96
2009 Janes MR, Fruman DA. Immune regulation by rapamycin: moving beyond T cells. Science Signaling. 2: pe25. PMID 19383976 DOI: 10.1126/scisignal.267pe25  0.6
2008 Fabre S, Carrette F, Chen J, Lang V, Semichon M, Denoyelle C, Lazar V, Cagnard N, Dubart-Kupperschmitt A, Mangeney M, Fruman DA, Bismuth G. FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. Journal of Immunology (Baltimore, Md. : 1950). 181: 2980-9. PMID 18713968  0.72
2008 Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. The Journal of Clinical Investigation. 118: 3038-50. PMID 18704194 DOI: 10.1172/JCI33337  0.6
2008 de Souza AJ, Oak JS, Jordanhazy R, DeKruyff RH, Fruman DA, Kane LP. T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase. Journal of Immunology (Baltimore, Md. : 1950). 180: 6518-26. PMID 18453570  1
2008 Yusuf I, Kharas MG, Chen J, Peralta RQ, Maruniak A, Sareen P, Yang VW, Kaestner KH, Fruman DA. KLF4 is a FOXO target gene that suppresses B cell proliferation. International Immunology. 20: 671-81. PMID 18375530 DOI: 10.1093/intimm/dxn024  0.96
2007 Oak JS, Matheu MP, Parker I, Cahalan MD, Fruman DA. Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Biochemical Society Transactions. 35: 1109-13. PMID 17956290 DOI: 10.1042/BST0351109  0.36
2007 Donahue AC, Kharas MG, Fruman DA. Measuring phosphorylated Akt and other phosphoinositide 3-kinase-regulated phosphoproteins in primary lymphocytes. Methods in Enzymology. 434: 131-54. PMID 17954246 DOI: 10.1016/S0076-6879(07)34008-1  0.96
2007 Oak JS, Fruman DA. Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity. 40: 433-41. PMID 17729037 DOI: 10.1080/08916930701464780  1
2007 Donahue AC, Fruman DA. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. European Journal of Immunology. 37: 2923-36. PMID 17724683 DOI: 10.1002/eji.200737281  0.88
2007 Matheu MP, Deane JA, Parker I, Fruman DA, Cahalan MD. Class IA phosphoinositide 3-kinase modulates basal lymphocyte motility in the lymph node. Journal of Immunology (Baltimore, Md. : 1950). 179: 2261-9. PMID 17675487  0.96
2007 Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood. 109: 2894-902. PMID 17164340 DOI: 10.1182/blood-2006-07-038620  0.96
2007 Kharas MG, Yusuf I, Scarfone VM, Yang VW, Segre JA, Huettner CS, Fruman DA. KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood. 109: 747-55. PMID 16954505 DOI: 10.1182/blood-2006-03-011106  0.96
2006 Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA. Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proceedings of the National Academy of Sciences of the United States of America. 103: 16882-7. PMID 17071741 DOI: 10.1073/pnas.0607984103  0.96
2006 Chen J, Yusuf I, Andersen HM, Fruman DA. FOXO transcription factors cooperate with delta EF1 to activate growth suppressive genes in B lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 176: 2711-21. PMID 16493026  1
2005 Cruz R, Hedden L, Boyer D, Kharas MG, Fruman DA, Lee-Fruman KK. S6 kinase 2 potentiates interleukin-3-driven cell proliferation. Journal of Leukocyte Biology. 78: 1378-85. PMID 16204634 DOI: 10.1189/jlb.0405225  0.96
2005 Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Research. 65: 2047-53. PMID 15781610 DOI: 10.1158/0008-5472.CAN-04-3888  0.96
2005 Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, Cantley LC. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Molecular and Cellular Biology. 25: 2593-606. PMID 15767666 DOI: 10.1128/MCB.25.7.2593-2606.2005  0.96
2004 Zhu X, Hart R, Chang MS, Kim JW, Lee SY, Cao YA, Mock D, Ke E, Saunders B, Alexander A, Grossoehme J, Lin KM, Yan Z, Hsueh R, Lee J, ... ... Fruman DA, et al. Analysis of the major patterns of B cell gene expression changes in response to short-term stimulation with 33 single ligands. Journal of Immunology (Baltimore, Md. : 1950). 173: 7141-9. PMID 15585835  0.96
2004 Donahue AC, Hess KL, Ng KL, Fruman DA. Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85alpha. International Immunology. 16: 1789-98. PMID 15520044 DOI: 10.1093/intimm/dxh180  0.96
2004 Hess KL, Donahue AC, Ng KL, Moore TI, Oak J, Fruman DA. Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. European Journal of Immunology. 34: 2968-76. PMID 15384044 DOI: 10.1002/eji.200425326  0.96
2004 Donahue AC, Fruman DA. PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Seminars in Cell & Developmental Biology. 15: 183-97. PMID 15209378  0.88
2004 Deane JA, Trifilo MJ, Yballe CM, Choi S, Lane TE, Fruman DA. Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase. Journal of Immunology (Baltimore, Md. : 1950). 172: 6615-25. PMID 15153476  0.96
2004 Yusuf I, Zhu X, Kharas MG, Chen J, Fruman DA. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood. 104: 784-7. PMID 15069012 DOI: 10.1182/blood-2003-09-3071  0.96
2004 Deane JA, Fruman DA. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annual Review of Immunology. 22: 563-98. PMID 15032589 DOI: 10.1146/annurev.immunol.22.012703.104721  0.96
2004 Kharas MG, Deane JA, Wong S, O'Bosky KR, Rosenberg N, Witte ON, Fruman DA. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 103: 4268-75. PMID 14976048 DOI: 10.1182/blood-2003-07-2193  0.96
2003 Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. The Journal of Biological Chemistry. 278: 48453-66. PMID 14504291 DOI: 10.1074/jbc.M305602200  0.96
2003 Yusuf I, Fruman DA. Regulation of quiescence in lymphocytes. Trends in Immunology. 24: 380-6. PMID 12860529  1
2003 Donahue AC, Fruman DA. Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation. Journal of Immunology (Baltimore, Md. : 1950). 170: 5851-60. PMID 12794110  0.88
2003 Hallmann D, Trümper K, Trusheim H, Ueki K, Kahn CR, Cantley LC, Fruman DA, Hörsch D. Altered signaling and cell cycle regulation in embryonal stem cells with a disruption of the gene for phosphoinositide 3-kinase regulatory subunit p85alpha. The Journal of Biological Chemistry. 278: 5099-108. PMID 12435753 DOI: 10.1074/jbc.M208451200  0.6
2002 Fruman DA, Cantley LC. Phosphoinositide 3-kinase in immunological systems. Seminars in Immunology. 14: 7-18. PMID 11884226 DOI: 10.1006/smim.2001.0337  0.6
2002 Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Molecular and Cellular Biology. 22: 965-77. PMID 11784871  0.6
2002 Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. The Journal of Clinical Investigation. 109: 141-9. PMID 11781359 DOI: 10.1172/JCI13305  0.6
2002 Fruman DA, Ferl GZ, An SS, Donahue AC, Satterthwaite AB, Witte ON. Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 99: 359-64. PMID 11756681 DOI: 10.1073/pnas.012605099  0.96
Show low-probability matches.